Press Release Summary:
Used for cholangioscopy and pancreatoscopy procedures, SpyGlass DS Direct Visualization System enables advanced diagnosis and treatment of pancreatico-biliary diseases. System consists of SpyScope™ DS Access and Delivery Catheter, and single-use scope to eliminate probe reprocessing and image degradation over multiple uses. Integrated digital sensor provides wide field of view and optimal imaging, while integrated controller fits on standard ERCP cart for accessibility and plug-and-play setup.
Original Press Release:
Boston Scientific Launches Next Generation SpyGlass(TM) DS Direct Visualization System for Advanced Diagnosis and Treatment of Pancreatico-biliary Diseases
MARLBOROUGH, Mass., -- Boston Scientific Corporation (NYSE: BSX) announces 510(k) clearance and the first cases of the SpyGlass DS Direct Visualization System used for cholangioscopy and pancreatoscopy procedures. Built on the technology of the original SpyGlass System, the new SpyGlass DS System is designed to optimize procedural efficiency and productivity with improved ease of setup, ease of use and image quality.
Experience the interactive Multimedia News Release here http://www.multivu.com/players/English/7223451-boston-scientific-spyglass-ds/
More than one million people worldwide undergo endoscopic retrograde cholangiopancreatography (ERCP) procedures each year to diagnose and treat diseases and conditions of the liver, gallbladder, pancreas and bile ducts.(1) In the event that x-ray imaging is not sufficient to make a definitive diagnosis or therapeutic intervention requires direct visualization, cholangioscopy or pancreatoscopy may be performed. Cholangioscopy is the examination of the bile ducts using an endoscope to enable direct visualization of the biliary tree during ERCP while pancreatoscopy is the examination of the pancreatic ducts. Direct visualization of the bile and pancreatic ducts during ERCP can help obtain biopsy specimens, lead to the diagnosis of abnormalities, and guide stone therapy.(2)
"I'm extremely pleased with the overall functionality of the new SpyGlass DS System," said Robert Hawes, M.D., FASGE, The Center for Interventional Endoscopy at Florida Hospital Orlando. "It was quick and easy to set up ('plug and play'), the image quality and stability excellent and the four-way tip deflection intuitive. The system now enables endoscopists with ERCP expertise to perform cholangioscopy with or without intervention. My expectation is that this technology will increase our ability to diagnose and treat pancreatobiliary diseases and reduce the number of repeat ERCPs."
Launched in 2007, the original SpyGlass System helped re-establish cholangioscopy and pancreatoscopy as a valuable diagnostic and therapeutic procedure by allowing a single physician to perform the procedure as well as guide devices to examine, diagnose and treat conditions such as gallstones and suspected malignancies of the biliary tree and pancreas. The new SpyGlass DS System builds on this technology with enhanced features to further improve visualization and help simplify the procedure. The system consists of a fully integrated SpyScope(TM) DS Access and Delivery Catheter, and a single-use scope to eliminate probe reprocessing and image degradation over multiple uses. The integrated digital sensor provides superior imaging, far greater resolution and a 60 percent wider field of view than the first generation system. In addition, the SpyGlass DS System offers physicians an integrated controller that fits on a standard ERCP cart for improved accessibility and 'plug and play' setup, helping to reduce procedure time.
"Early detection is critical to improving outcomes in patients suffering from difficult pancreatico-biliary diseases, such as pancreatic cancer," said David Pierce, senior vice president and president, Endoscopy, Boston Scientific. "The new SpyGlass DS System can be performed as an extension of any ERCP procedure, enabling physicians to diagnose and treat more of their patients effectively and efficiently. Boston Scientific is proud to bring single-operator cholangioscopy to a new level of treatment."
(1 )Chen Y et al, Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc 2011; 74:805-814.
(2 )CPT Copyright 2014 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Media: Nisha Deo
Global Media Relations
Boston Scientific Corporation